コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 n various solid organ transplants but not in intestinal transplantation.
2 , including 8 who were weaned from TPN after intestinal transplantation.
3 have greatly improved patient outcomes after intestinal transplantation.
4 pot specimen citrulline concentrations after intestinal transplantation.
5 inal failure is considered an indication for intestinal transplantation.
6 igate the physiology and immunology of small-intestinal transplantation.
7 to address the risk of de novo cancer after intestinal transplantation.
8 mia/reperfusion injury associated with small intestinal transplantation.
9 s commonly isolated from children undergoing intestinal transplantation.
10 -associated liver disease is reversible with intestinal transplantation.
11 ansplantation and require combined liver and intestinal transplantation.
12 ion should prompt consideration for isolated intestinal transplantation.
13 free survival can be achieved after isolated intestinal transplantation.
14 rst-line treatment of CD20 B-cell PTLD after intestinal transplantation.
15 ion in a rodent orthotopic survival model of intestinal transplantation.
16 h PTLD from March 1999 to August 2001, after intestinal transplantation.
17 ight improve the overall outcome of isolated intestinal transplantation.
18 o-mismatch allografts for cadaveric isolated intestinal transplantation.
19 ronic intestinal rejection in a rat model of intestinal transplantation.
20 for the induction of apoptosis in rat small intestinal transplantation.
21 course and complex management that accompany intestinal transplantation.
22 and can be used for preemptive therapy after intestinal transplantation.
23 raction to alloimmune response is unknown in intestinal transplantation.
24 mucosa at the single-cell level after human intestinal transplantation.
25 regulates allograft tissue injury in murine intestinal transplantation.
26 s to question the need for stoma creation in intestinal transplantation.
27 of using teduglutide compared with offering intestinal transplantation.
28 arrier to improving long-term outcomes after intestinal transplantation.
29 eceiving HPN were eventually eligible for an intestinal transplantation.
30 of our prophylaxis and treatment regimens in intestinal transplantation.
31 ributes to ischemia-reperfusion injury after intestinal transplantation.
32 ot appear to confer survival advantage after intestinal transplantation.
33 parenteral nutrition dependence and need for intestinal transplantation.
34 risk factors for GVHD development following intestinal transplantation.
35 nting postoperative dysmotility for clinical intestinal transplantation.
36 ntestinal physiology following resection and intestinal transplantation.
37 eral nutrition in a series of children after intestinal transplantation.
38 d, it is hoped, help revitalize the field of intestinal transplantation.
39 were sent to 50 centers performing pediatric intestinal transplantation.
40 s of abdominal domain is a common problem in intestinal transplantation.
41 in generally accepted referral criteria for intestinal transplantation.
42 oxidant and anti-inflammatory effects in rat intestinal transplantation.
43 l failure patients including those requiring intestinal transplantation.
44 ning from parenteral nutrition, and need for intestinal transplantation.
45 ully selected patients and does not preclude intestinal transplantation.
46 rative relationships with centers performing intestinal transplantation; (3) National registries for
47 With the more frequent use of pancreatic and intestinal transplantation, a procurement procedure is n
51 dentify potential new criteria for pediatric intestinal transplantation among transplant centers in E
52 etransplantation was performed in 3 isolated intestinal transplantation and 9 multivisceral transplan
54 toring will ease sample collection following intestinal transplantation and improve the ability to de
55 is review is to update the current status of intestinal transplantation and its role in the managemen
56 of life typically improves after successful intestinal transplantation and may support the decision
57 help define the pool of potential donors for intestinal transplantation and propose methods for an in
58 tality in adults and children candidates for intestinal transplantation and provide recommendations o
59 sease, which may preclude them from isolated intestinal transplantation and require combined liver an
60 eaned off of HPN, 9% of the PDD subgroup had intestinal transplantation, and 10% died mostly because
63 tion (TPN) or more frequently considered for intestinal transplantation as part of their treatment pr
64 reventing the more widespread application of intestinal transplantation as treatment for intestinal f
67 lied to stratify all patients that underwent intestinal transplantation at the University of Miami be
70 raised in humans after total gastrectomy or intestinal transplantation, but largely unresponsive to
71 losure of the abdomen in patients undergoing intestinal transplantation can be extremely difficult, i
78 esponse to ischemia reperfusion injury after intestinal transplantation contributing to graft dysmoti
79 or ABO incompatibility may be tolerated with intestinal transplantation, despite the transplantation
88 leocecal valve in patients receiving primary intestinal transplantation has not been performed in a s
90 ding changes in small bowel physiology after intestinal transplantation has received less attention.
94 ker for acute cellular rejection (ACR) after intestinal transplantation; however, its clinical utilit
95 marker for acute cellular rejection (ACR) in intestinal transplantation; however, its significance as
96 ion and its associated side effects preclude intestinal transplantation if motivated only by an expec
97 transplantation, and recipients of isolated intestinal transplantation (IIT)/multivisceral transplan
99 was published that described indications for intestinal transplantation in patients with intestinal f
100 ese teams, patients should be considered for intestinal transplantation in the event of progressive i
101 on, reverses complications of TPN and avoids intestinal transplantation in the majority with few surg
102 ing teduglutide in conjunction with offering intestinal transplantation in US pediatric patients with
103 8 months, risk factors affecting survival to intestinal transplantation include small body size and a
107 this function is impaired in the setting of intestinal transplantation into a NOD2 mutant recipient.
115 of suitable donors and listed recipients for intestinal transplantation is small, resulting in diffic
121 ovirus (CMV) prevention and treatment across intestinal transplantation (IT) programs is unknown.
122 Deciding which patients would benefit from intestinal transplantation (IT) remains an ethical/clini
123 emia-reperfusion injury is inevitable during intestinal transplantation (ITx) and executes a key role
124 diagnosis of acute and chronic rejection in intestinal transplantation (ITX) are far from being comp
126 n (HPN) to that among patients who underwent intestinal transplantation (ITx) at the University of Pi
131 rent rejection shortens graft survival after intestinal transplantation (ITx) in children, most of wh
133 mismatches in a clinically relevant model of intestinal transplantation (ITx) in swine with defined M
142 meostatic regulation, and graft rejection in intestinal transplantation (ITx) patients have yet to be
155 r single-center experience with living donor intestinal transplantation (LDITx) and combined living d
156 r those with life-threatening complications, intestinal transplantation may soon be an option for any
158 n lifestyle associated with long-term TPN or intestinal transplantation or both, it seems prudent to
159 d include both intestinal rehabilitation and intestinal transplantation or have active collaborative
166 The cost of parenteral nutrition compared to intestinal transplantation reveals that transplantation
170 disease (PTLD) has a higher incidence after intestinal transplantation than after transplantation of
171 racing approaches, biophysical modelling and intestinal transplantation, that all cells of the mouse
172 ed parenteral nutrition is higher than after intestinal transplantation, the 1 and 2 year survival is
173 ic and functional graft protection in rodent intestinal transplantation, ultimately facilitating reci
177 es in a group of 22 pediatric patients after intestinal transplantation, we assessed mucosal disaccha
178 specific risk factors impacting survival to intestinal transplantation, we performed a 4-year instit
180 ast year, initial attempts at adult to child intestinal transplantation were carried out with some su
181 undergoing concomitant or prior liver and/or intestinal transplantation were excluded from analysis.
182 undergoing concomitant or prior liver and/or intestinal transplantation were not included in the anal
183 atients awaiting kidney, liver, pancreas, or intestinal transplantation were pretreated with about 5
185 milarly, allogeneic and syngeneic orthotopic intestinal transplantations were performed in tacrolimus
188 ed patients to successfully undergo isolated intestinal transplantation with acceptable short-term ou
189 sion-free closure of the fascial layer after intestinal transplantation with complications similar to